Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Irbesartan decreases monocyte binding the CD11b monoclonal antibody in patients with coronary artery disease (CAD). Patients with CAD were placed on placebo or irbesartan (150 mg/day) for a 12-week period. Serum samples were collected and red blood cells were lysed. Using flow cytometry analysis, whole-blood monocyte CD11b expression was performed. The values expressed are a percentage of expression of CD11b by circulating monocytes. The p value, as determined by analysis of variance, was <0.0001 for time, for group and for the group-time interaction. Black square = placebo; white square = irbesartan; *p < 0.05 = difference between 0 weeks and 4 or 12 weeks within each group; #p < 0.05 = difference between placebo and irbesartan groups.
|
